On paper, things should be looking up for Japan’s pharmaceutical wholesalers. Industry expectations are mounting that the average gap between NHI and market prices will narrow further in FY2026 from the previous year’s record low of 4.8%.A shrinking gap should…
HOME > REGULATORY
REGULATORY
- Amended PMD Law Set for 3-Step Enforcement, 1st Execution Eyed Next Autumn
November 28, 2019
- LDP to Forge Lawmakers’ League Aimed to Reinstate HPV Vaccine Recommendation
November 27, 2019
- “All-Generation” Panel Cites Coverage of OTC-Like Drugs as Policy Issue
November 27, 2019
- Japan Enacts Amended Pharmaceuticals and Medical Devices Law
November 27, 2019
- Japan’s First Biosimilars of Avastin, Nesp, Forteo Receive Listing
November 27, 2019
- MOF Panel Leery of Pricey Drugs for Huge Patient Population: FY2020 Budget Recommendation
November 26, 2019
- MHLW Panel OKs Bayer’s Xtandi Rival, AbbVie’s JAK Inhibitor; 2 More Keytruda Usages Now in Line for Approval
November 26, 2019
- MHLW Panel Members Call for Need to “at Least Discuss” Whether to Resume Actively Recommending HPV Vaccines
November 26, 2019
- Plaintiffs of HPV Vaccine Suits Prod JMA to Hear Stories of Victims
November 26, 2019
- MHLW Floats 2 Rules to Address Unreasonable Price Rises for Listed Generics
November 26, 2019
- Xolair’s Pollen Allergy Nod Delayed as Novartis Says It Needs More Time to Prepare for Launch
November 25, 2019
- Chuikyo Members Remain Divided over Timing of Comparator PMP Removal
November 25, 2019
- MHLW Wants to Subject Innovative Add’l Use to PMP, but No Price Raise
November 25, 2019
- MHLW Wants to Ease Unfairness Concerns by Adding New Innovation Gauge to PMP Company Criteria
November 25, 2019
- Industry Urges Careful Approach to Creating Special Rule for Indication Change Re-Pricing: Chuikyo
November 25, 2019
- Japan Approves Add’l Indications for Taltz, Lucentis and More
November 25, 2019
- No Change to Essential Drug Rule in 2020 Reform: MHLW
November 25, 2019
- MHLW Proposes Earlier Price Cuts for Off-Patent Drugs with 80%-Plus Gx Rates, but Chuikyo Questions 2-Year Grace Period
November 25, 2019
- MHLW Proposes Continued Discussions for Cell & Gene Therapy Pricing
November 25, 2019
- PIC/S Reports State of Discussions on Data Integrity Guidance in Japan Meeting: MHLW
November 25, 2019
ページ
Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
As Japan’s budget season draws near, the Ministry of Finance (MOF) has renewed its push for a full-scale “off-year” drug…
Japan will trim the NHI price of Eli Lilly Japan’s Alzheimer’s treatment Kisunla (donanemab) by 3.93% under the cost-effectiveness assessment…
Japan is set to add 16 new drugs to its NHI reimbursement price list on November 13, including a subcutaneous…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…